Masimo (NASDAQ:MASI) Releases Q4 2024 Earnings Guidance

Masimo (NASDAQ:MASI) issued an update on its fourth quarter 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 1.350-1.500 for the period, compared to the consensus estimate of 1.410. The company issued revenue guidance of $581.0 million-$611.0 million, compared to the consensus revenue estimate of $607.4 million. Masimo also updated its FY24 guidance to $3.95-$4.10 EPS.

Masimo Stock Up 2.8 %

NASDAQ MASI traded up $4.17 on Tuesday, reaching $151.56. The company had a trading volume of 1,309,932 shares, compared to its average volume of 675,776. The firm has a market capitalization of $8.06 billion, a PE ratio of 103.10 and a beta of 0.97. The firm has a 50-day moving average of $130.02 and a 200-day moving average of $125.22. Masimo has a 1 year low of $75.36 and a 1 year high of $153.93. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.15.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. The business had revenue of $496.30 million during the quarter, compared to analyst estimates of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The business’s revenue was up 9.0% on a year-over-year basis. During the same period last year, the business earned $0.62 EPS. On average, equities research analysts anticipate that Masimo will post 3.88 EPS for the current fiscal year.

Analysts Set New Price Targets

MASI has been the topic of several recent analyst reports. Piper Sandler reiterated an “overweight” rating on shares of Masimo in a research note on Friday, October 18th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Friday, September 20th. Finally, BTIG Research raised their price target on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Masimo has a consensus rating of “Moderate Buy” and a consensus price target of $145.33.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.